Try our Advanced Search for more refined results
February 13, 2018
Kim v. Cascadian Therapeutics, Inc. et al
Case Number:
1:18-cv-00250
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
February 14, 2018
Cascadian Investor Says $614M Deal Statement Omitted Info
A shareholder of biopharmaceutical company Cascadian Therapeutics Inc. launched a class action on Tuesday in Delaware federal court alleging the company's directors omitted material information from documents detailing a proposed $614 million merger deal with Seattle Genetics Inc.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login